|
|
|
|
| 06.26.07 |
|
 KOS 2007: Molecular Principles Underlying Myeloma
|
|
|
P. Leif Bergsagel, MD
Mayo Clinic
Scottsdale, AZ, USA
|
|
|
|
| |
 |
|
|
| 06.26.07 |
|
 KOS 2007: Molecular Lesions in Multiple Myeloma
|
|
|
Michael Kuehl, MD
National Cancer Institute
Bethesda, MD, USA
|
|
|
|
| |
|
|
|
| 06.26.07 |
|
 KOS 2007: Towards a Molecular-Based Risk Stratification of Multiple Myeloma
|
|
|
J.D. Shaughnessy Jr., MD
Donna D. and Donald M. Lambert Laboratory for Myeloma Genetics
Myeloma Institute for Research and Therapy
University of Arkansas for Medical Sciences
Little Rock, Arkansas, USA
|
|
|
|
| |
|
|
|
| 06.26.07 |
|
 KOS 2007: Clinical and Pathological Implications of Myeloma Subtypes
|
|
|
Rafael Fonseca, MD
Mayo Clinic
Scottsdale, AZ, USA
|
|
|
|
| |
|
|
|
| 06.26.07 |
|
 KOS 2007: Prognostic implications of FISH karyotyping in Myeloma
|
|
|
Herve Avet-Loiseau, MD
Laboratory of Hematology
University Hospital
Nantes, France
|
|
|
|
| |
|
|
|
| 06.26.07 |
|
 KOS 2007: Single Nucleotide Polymorphism Models in Myeloma - From the Bank On A Cure SNP Chip
|
|
|
Brian Van Ness, PhD
Bank On A Cure®
International Myeloma Foundation
|
|
|
|
| |
|
|
|
|
|
|
|
| 06.26.07 |
|
 KOS 2007: Animal Models of Multiple Myeloma: An Overview
|
|
|
Karin Vanderkerken, MD
Vrije Universiteit Brussel (VUB)
Department Hematology and Immunology
Brussels, Belgium
|
|
|
|
| |
|
|
|
| 06.26.07 |
|
 KOS 2007: The Scid-hu model for Multiple Myeloma
|
|
|
Joshua Epstein, MD
Myeloma Institute for Research and Therapy
University of Arkansas for Medical Sciences
Little Rock, Arkansas, USA
|
|
|
|
| |
|
|
|
| 06.26.07 |
|
KOS 2007: Chromosomal and epigenetic abnormalities in MGUS and MM Post-MGUS
|
|
|
Johannes Drach, MD
Medical University of Vienna
Department of Medicine I
Clinical Division of Oncology
Vienna, Austria
|
|
|
|
| |
|
|
|
| 06.26.07 |
|
 KOS 2007: Microarray Analysis to Predict Response to Thalidomide and the IMIDs
|
|
|
Shaji Kumar, MD
Mayo Clinic
Hepatology Department
Rochester, MN, USA
|
|
|
|
| |
|
|
|
| 06.26.07 |
|
KOS 2007: Mosaicism of Vessels in Patients with Myeloma and Therapeutic Approaches
|
Angelo Vacca, MD
Department of Internal Medicine and Clinical Oncology
University of Bari Medical School
Bari, Italy
|
|
|
|
| |
|
|
|
| 06.26.07 |
|
 KOS 2007: The Role of T-Cells in Multiple Myeloma
|
|
|
Douglas Joshua, MD
University of Sydney
Royal Prince Alfred and Concord Hospital
Camperdown, Australia
|
|
|
|
| |
|
|
|
| 06.26.07 |
|
KOS 2007: Genetic Model of Multiple Myeloma
|
Ruben Carrasco, MD
Dana Farber Cancer Institute
Medical Oncology Dept.
Boston, MA, USA
(Presentation given by Giovanni Tonon)
|
|
|
|
| |
|
|
|
| 06.26.07 |
|
 KOS 2007: From Oncogenome Mining to Functional Validation of Multiple Myeloma Cancer Genes
|
|
|
Giovanni Tonon, MD
Dana Farber Cancer Institute
Medical Oncology Dept.
Boston, MA, USA
|
|
|
|
| |
|
|
|
|
|
|
|
| 06.26.07 |
|
 KOS 2007: Induction of Multi-Lineage Markers and Their Down-Regulation by IL-6 in Human Myeloma Cells
|
|
|
Michio Kawano, MD
Laboratory of Cellular Signal Analysis
Graduate School of Medicine
Yamaguchi University
Ube, Japan
|
|
|
|
| |
|
|
|
| 06.26.07 |
|
 KOS 2007: Pathophysiology of Myeloma Bone Disease
|
|
|
Peter Croucher, MD
Section of Musculoskeletal Science
University of Sheffield Medical School
Sheffield, UK
|
|
|
|
| |
|
|
|
| 06.26.07 |
|
 KOS 2007: The Role of Biochemical Markers of Bone Metabolism in Multiple Myeloma. Adverse Events of Bisphosphonates Administration
|
|
|
Evangelos Terpos, MD
Department of Hematology & Medical Research
251 General Airforce Hospital
Athens, Greece
|
|
|
|
| |
|
|
|
| 06.26.07 |
|
 KOS 2007: The Role of Bisphosphonates in the Management of Myeloma
|
|
|
James Berenson, MD
Institute for Myeloma and Bone Cancer Research
Los Angeles, CA, USA
|
|
|
|
| |
|
|
|
| 06.26.07 |
|
KOS 2007: New Agents Targeting Myeloma Bone Disease
|
|
|
G. David Roodman
University of Pittsburgh
Medicine/Hematology-Oncology
Pittsburgh, PA, USA
|
|
|
|
| |
|
|
|
| 06.26.07 |
|
 KOS 2007: A transgenic mouse model that faithfully reproduces the pathogenesis, biology and clinical features of multiple myeloma
|
|
|
Marta Chesi, MD
Comprehensive Cancer Center
Mayo Clinic Arizona
Scottsdale, AZ, USA
|
|
|
|
| |
|
|
|
|
|
|
|
| 06.27.07 |
|
 KOS 2007: The Treatment of Relapsed and Refractory Myeloma: Focus on Bortezomib and Bortezomib-based Combinations
|
|
|
Paul Richardson, MD
Medical Oncology
Dana Farber Cancer Institute
Harvard Medical School
Boston, MA, USA
|
|
|
|
| |
|
|
|
| 06.27.07 |
|
 KOS 2007: Lenalidomide for the Treatment of Relapsed or Refractory Myeloma
|
|
|
Donna Weber, MD
The University of Texas MD Anderson Cancer Center
Houston, TX, USA
|
|
|
|
| |
|
|
|
| 06.27.07 |
|
 KOS 2007: Impact of novel agents in patients with poor prognosis myeloma defined by unfavorable cytogenetics, high age, and renal failure
|
|
|
Heinz Ludwig, MD
Department of Medicine I
Center of Oncology and Hematology
Wilhelminenspital
Vienna, Austria
|
|
|
|
| |
|
|
|
|
|
|
|
| 06.27.07 |
|
 KOS 2007: International Staging System for Multiple Myeloma
|
|
|
Philip Greipp, MD
Mayo Clinic
Internal Medicine
Rochester, Minnesota
|
|
|
|
| |
|
|
|
| 06.27.07 |
|
 KOS 2007: The Role of Thalidomide in Myeloma Patients Eligible for High-Dose Therapy
|
|
|
Michele Cavo, MD
Seràgnoli Institute of Hematology and Medical Oncology
Bologna UniversitySchool of Medicine
Italy
|
|
|
|
| |
|
|
|
| 06.27.07 |
|
KOS 2007: Role of Bortezomib in Myeloma Patients Eligible for High-Dose Therapy
|
|
|
Sundar Jagannath, MD
St. Vincent's Comprehensive Cancer Center
New York, NY, USA
|
|
|
|
| |
|
|
|
| 06.27.07 |
|
 KOS 2007: The Role of Lenalidomide in Myeloma Patients Eligible for High Dose Therapy
|
|
|
Vincent Rajkumar, MD
Division of Hematology
Mayo Clinic
Rochester, Minnesota, USA
|
|
|
|
| |
|
|
|
| 06.27.07 |
|
 KOS 2007: Frontline Treatment in Patients Not Eligible for Stem Cell Transplant
|
|
|
Thierry Facon, MD
CHU
Lille, France
|
|
|
|
| |
|
|
|
| 06.27.07 |
|
 KOS 2007: Management of Toxicities from Novel Agents
|
|
|
Mohamad Hussein, MD
Multiple Myeloma Clinical Research Clinical Director
H. Lee Moffitt Cancer & Research Institute
Tampa, Florida, USA
|
|
|
|
| |
|
|
|
| 06.27.07 |
|
 KOS 2007: Prognostic Factors for Multiple Myeloma in the Era of Novel Therapies
|
|
|
Joan Bladé
Hematology Department
Institut of Hematology and Oncology
IDIBAPS, HospitalClínic
Barcelona, Spain
|
|
|
|
| |
|
|
|
|
|
|
|
| 06.27.07 |
|
 KOS 2007: Debate I - Should CR Achievement Be a Major Treatment Objective?
Introduction
|
|
|
Raymond Alexanian, MD
|
|
|
|
| |
|
|
|
| 06.27.07 |
|
 KOS 2007: Debate I - Should CR Achievement Be a Major Treatment Objective? Yes!
|
|
|
Jean Luc Harousseau, MD
Hôpital Hôtel Dieu
Nantes, France
|
|
|
|
| |
|
|
|
| 06.27.07 |
|
 KOS 2007: Debate I - Should CR Achievement Be a Major Treatment Objective? No!
|
|
|
Mario Boccadoro, MD
Divisione di Ematologia dell’Università di Torino
Azienda Ospedaliera San Giovanni Battista
Torino, Italy
Includes questions and comments from the audience.
|
|
|
|
| |
|
|
|
|
|
|
|
| 06.27.07 |
|
 KOS 2007: Establishment of an Amyloid-Forming Human Cell Line
|
|
|
Bonnie Arendt, MD
Dept. of Immunology
Mayo Cinic
Rochester, MN, USA
|
|
|
|
| |
|
|
|
| 06.27.07 |
|
KOS 2007: Targeting Beta 1 Integrin Mediated Survival Signals in Multiple Myeloma
|
Lori Hazlehurst, PhD
Moffitt Cancer Center
Tampa, Florida, USA
|
|
|
|
| |
|
|
|
| 06.27.07 |
|
KOS 2007: Response by SFLC and Marrow Flow Cytometry in MRC Myeloma IX
|
Roger Owen, MD
HMDS Laboratory and Department of Haematology
Leeds Teaching Hospitals
Leeds, UK
|
|
|
|
| |
|
|
|
|
|
|
|
| 06.27.07 |
|
KOS 2007: Final Results of a Phase II PETHEMA Trial of Alternating Bortezomib and Dexamethasone as Induction Regimen Prior Autologous Stem Cell Transplantation (ASCT) in YOunger Patients with Multiple Myeloma (MM): Efficacy and Clinical Implications of Tumor Response Kinetics
|
|
|
Laura Rosiñol, MD
Hospital Clinic
Barcelona, Spain
|
|
|
|
| |
|
|
|
| 06.27.07 |
|
KOS 2007: Long-Term and Updated Results of the IFM99-03 and IFM99-04 ProtocolsComparing Autologous Followed by RIC-Allogeneic Transplantation and Double Transplant in High-Risk De Novo Multiple Myeloma
|
|
|
Philippe Moreau, MD
on Behalf of the IFM Group
France
|
|
|
|
| |
|
|
|
| 06.27.07 |
|
KOS 2007: Double versus Single Autologous Stem-Cell Transplantation for Multiple Myeloma: a Region Based Study in 485 patients from the Nordic Area
|
H.E. Johnsen, MD
Department of Hematology
Huddinge University Hospital
Sweden
|
|
|
|
| |
|
|
|
| 06.27.07 |
|
KOS 2007: Prognostic impact of postransplantation complete remission (CR) in multiple myeloma(MM). Final results of a prospective study in a series of homogenously treated patients
|
Joaquin Martinez-Lopez
the Grupo Espanol de Mieloma (GEM)
Spain
|
|
|
|
| |
|
|
|
|
|
|
|
| 06.28.07 |
|
KOS 2007: Drug Resistance in Myeloma
|
|
|
W.S. Dalton, MD
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, USA
|
|
|
|
| |
|
|
|
| 06.28.07 |
|
 KOS 2007: AKT as a Therapeutic Target in Multiple Myeloma
|
|
|
Noopur Raje, MD
Massachusetts General Hospital Cancer Center
Boston, MA, USA
|
|
|
|
| |
|
|
|
| 06.28.07 |
|
KOS 2007: DNA Vaccines to Suppress Myeloma
|
|
|
Freda Stevenson, MD
Molecular Immunology Group
Cancer Sciences Division
Tenovus Laboratory
Southampton University Hospitals Trust
Southampton, UK
|
|
|
|
| |
|
|
|
| 06.28.07 |
|
 KOS 2007: Novel Immunotherapy Strategies in Multiple Myeloma
|
|
|
Nikhil Munshi, MD
Dana Farber Cancer Institute
Boston MA, USA
|
|
|
|
| |
|
|
|
|
|
|
|
| 06.28.07 |
|
KOS 2007: Single VS Double Autologous Transplant
|
|
|
Hartmut Goldschmidt, MD
Medizinischen Universitätsklinik und Poliklinik V
University of Heidelberg
Heidelberg, Germany
|
|
|
|
| |
|
|
|
| 06.28.07 |
|
 KOS 2007: Autologous Stem Cell Transplantation for MM: Analysis of Prognostic Factors
|
|
|
Hermann Einsele, MD
Medizinische Klinik und Poliklinik I
Bayerische Julius-Maximilians-Universität Würzburg
|
|
|
|
| |
|
|
|
| 06.28.07 |
|
Kos 2007: Allogeneic Transplantation in Multiple Myeloma
|
|
|
Henk Lokhorst, MD
Dept. of Hematology
University Medical Center Utrecht, the Netherlands
|
|
|
|
| |
|
|
|
| 06.28.07 |
|
KOS 2007: Donor lymphocyte infusion and other posttransplant Strategies After Allografting in Multiple Myeloma
|
|
|
Nikolaus Kröger
Dept. of Stem Cell Transplantation
University Hospital Hamburg-Eppendorf, Germany
|
|
|
|
| |
|
|
|
|
|
|
|
| 06.28.07 |
|
KOS 2007: Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM)
|
|
|
Robert A. Kyle, MD
Mayo Clinic
Rochester, MN, USA
|
|
|
|
| |
|
|
|
| 06.28.07 |
|
 KOS 2007: Solitary Bone and Extramedullary Plasmacytoma
|
|
|
Raymond Alexanian, MD
M. D. Anderson Cancer Center
University of Texas
Houston, TX, USA
|
|
|
|
| |
|
|
|
| 06.28.07 |
|
 KOS 2007: AL Amyloidosis: Diagnosis and Prognosis
|
Giampaolo Merlini, MD
Amyloidosis Center
Fondazione IRCCS Policlinico San Matteo
University of Pavia
Pavia, Italy
|
|
|
|
| |
|
|
|
| 06.28.07 |
|
 KOS 2007: AL Amyloidosis: Response, Assessment, and Treatment
|
|
|
Morie A. Gertz, MD
Mayo Clinic
Rochester, MN, U.S.A.
|
|
|
|
| |
|
|
|
| 06.28.07 |
|
 KOS 2007: The Role of High-Dose Therapy in AL-Amyloidosis
|
|
|
Raymond Comenzo, MD
Hematology Service
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, NY, USA
|
|
|
|
| |
|
|
|
| 06.28.07 |
|
 KOS 2007: Light Chain Deposition Disease
|
|
|
Nelson Leung, MD
Mayo Clinic
Rochester, MN, USA
|
|
|
|
| |
|
|
|
| 06.28.07 |
|
 KOS 2007: What’s New About the POEMS Syndrome?
|
|
|
Angela Dispenzieri, MD
Mayo Clinic Cancer Center
Rochester, MN, USA
|
|
|
|
| |
|
|
|
| 06.28.07 |
|
 KOS 2007: Paraproteinemia Related Neuropathies
|
Eduardo Nobile-Orazio, MD
Department of Neurological Sciences
Milan University
Milan, Italy
|
|
|
|
| |
|
|
|
|
|
|
|
| 06.29.07 |
|
KOS 2007: High-Resolution Mapping of Common Gains and Losses in Myeloma
|
Jonathan Keats,MD
Mayo Clinic Comprehensive Cancer Center
Scottsdale, Arizona, USA
|
|
|
|
| |
|
|
|
| 06.29.07 |
|
KOS 2007: Microchips for Optimized Fish Screening in Myeloma
|
Vincent Sieben
Department of Electrical & Computer Engineering
University of Alberta
Edmonton, Canada
|
|
|
|
| |
|
|
|
| 06.29.07 |
|
KOS 2007: Gene Expression Profiles as Prognostic Factors for High-Dose Therapy and Bortezomib in Patients with Multiple Myeloma
|
Annemiek Broyl, MD
Department of Hematology
Erasmus Medical Center
Rotterdam, The Netherlands
|
|
|
|
| |
|
|
|
| 06.29.07 |
|
KOS 2007: Cathepsin G is Upregulated in Patients Treated with IMIDS
|
|
|
Suzanne Lentzsch, MD
University of Pittsburgh Cancer Institute
Pittsburgh, PA, USA
|
|
|
|
| |
|
|
|
| 06.29.07 |
|
KOS 2007:Melphalan-Prednisone-Thalidomide (MP-T) is Also Superior to Melphalan-Prednisone (MP) in Patients 75 Years of Age or Older with Untreated Multiple Myeloma (MM). Preliminary Results of the Randomized, Double-Blind, Placebo Controlled IFM 01-01 Trial
|
Cyrille Hulin, MD
Itergroupe Francophone du Myélome
|
|
|
|
| |
|
|
|
|
|
|
|
| 06.29.07 |
|
KOS 2007: Debate II - Should autologous transplant be part of the primary treatment in MM?
Introduction
|
|
|
| |
|
|
|
| 06.29.07 |
|
 KOS 2007: Debate II - Should autologous transplant be part of the primary treatment in MM? NO
|
Jean-Paul Fermand, MD
Department of Immuno-Hematology
Hopital Saint-Louis, France
|
|
|
|
| |
|
|
|
| 06.29.07 |
|
 KOS 2007: Debate II - Should autologous transplant be part of the primary treatment in mm? YES
|
|
|
Bart Barlogie, MD
Myeloma Institute for Research and Therapy
University of Arkansas for Medical Sciences
Little Rock, AR, USA
|
|
|
|
| |
|
|
|
| 06.29.07 |
|
KOS 2007: Debate II - Should autologous transplant be part of the primary treatment in MM?
Q & A
|
|
Questions from Dr. Harousseau and the audience.
|
|
|
|
| |
|
|
|
|
|
|
|
| 06.29.07 |
|
 KOS 2007: The Importance of New and Evolving Response Criteria
|
|
|
Brian G.M. Durie, MD
Samuel Oschin Comprehensive Cancer Institute
Cedars Sinai Medical Center
Los Angeles, CA, USA
|
|
|
|
| |
|
|
|
| 06.29.07 |
|
 KOS 2007: Individualizing Treatment in the Area of Multiple Novel Agents
|
|
|
Jesús San Miguel, MD
Hospital Clinico Universitario
Universidad de Salamanca
Salamanca, Spain
|
|
|
|
| |
|
|
|
| 06.29.07 |
|
 KOS 2007: European Myeloma Network: The Present and the Future
|
|
|
Pieter Sonneveld
The European Myeloma Network (EMN)
|
|
|
|
| |
|
|
|
| 06.29.07 |
|
KOS 2007: Future Perspectives in the Management of Myeloma
|
|
|
Kenneth C. Anderson, MD
Dana-Farber Cancer Institute
Boston, MA, USA
|
|
|
|
| |
|
|
|
|
:
:
:
:
:
:
:
:
:
:
:
:
:
:
